JAK2 and diabetes mellitus: The administration of a JAK1/JAK2 inhibitor (LN3103801) slowed the development of anti-PD-L1-induced diabetes in NOD mice by blocking IFN-γ’s function on beta-cells and common gamma chain cytokine activities in T cells, providing preclinical validations for the use of JAK inhibitors in checkpoint inhibitor-induced diabetes [198].